NASDAQ$EVLO
Evelo Biosciences Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported positive data for EDP1815 in psoriasis and advanced EDP1815 towards later-stage clinical trials.
Evelo Biosciences reported first quarter 2022 financial results, highlighting positive data for EDP1815 in psoriasis and the advancement of EDP1815 towards later-stage clinical trials. The company's cash and cash equivalents were $39.6 million as of March 31, 2022.
- Reported positive data for EDP1815 in psoriasis, demonstrating effects on systemic inflammatory cytokine markers.
- Showed depth and duration of response at 6-month follow-up post dosing for EDP1815 in psoriasis.
- Observed increased target site engagement with a faster release capsule for EDP1815 in psoriasis.
- Recruitment is ahead of plan in Phase 2 trial of EDP1815 in atopic dermatitis, with data expected in Q1 and Q2 2023.
Headline financials
Revenue & EPS history
Evelo · Revenue · Quarterly
$0
Forward guidance
Evelo Biosciences anticipates data from the first 3 cohorts of the Phase 2 atopic dermatitis trial in mild, moderate, and severe atopic dermatitis in 1Q 2023, with data from a potential additional fourth cohort anticipated in 2Q 2023. The company also plans to initiate clinical development of EDP2939 in 3Q 2022 and expects Phase 2 data from a cohort of patients with psoriasis in 2H 2023.
Tailwinds
- Anticipates data from the first 3 cohorts of the Phase 2 atopic dermatitis trial in 1Q 2023.
- Potential data from a fourth cohort in the Phase 2 atopic dermatitis trial anticipated in 2Q 2023.
- Plans to initiate clinical development of EDP2939 in 3Q 2022.
- Expects Phase 2 data from a cohort of patients with psoriasis in 2H 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+1.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-9.7%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+32.3%
Q2 2023
Best reaction
-20.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2023 | +0.0% | +0.0% | -9.8% | |
| Q3 2023 | -7.6% | +4.5% | +3.8% | |
| Q2 2023 | +32.3% | -30.5% | -41.0% | |
| Q1 2023 | +2.9% | +10.2% | -28.8% | |
| Q4 2022 | -17.8% | -27.0% | -46.9% | |
| Q3 2022 | +3.3% | -3.3% | -8.5% | |
| Q2 2022 | -7.1% | -10.5% | -25.4% | |
| Q1 2022 | -20.3% | -14.5% | -2.4% | |
| Q4 2021 | +29.4% | +13.5% | -26.3% | |
| Q3 2021 | +10.2% | +27.0% | +6.0% | |
| Q2 2021 | -0.9% | +5.0% | +20.7% | |
| Q1 2021 | +8.8% | -14.4% | +11.0% | |
| Q4 2020 | +14.5% | +21.2% | +1.6% | |
| Q3 2020 | -12.9% | -5.9% | +14.0% | |
| Q2 2020 | -1.6% | -0.5% | +15.2% | |
| Q1 2020 | -5.7% | -14.0% | -20.9% | |
| Q4 2019 | +1.8% | +12.2% | -28.4% | |
| Q3 2019 | -3.3% | -6.1% | -35.9% | |
| Q2 2019 | +3.9% | -2.2% | +7.0% | |
| Q1 2019 | +0.8% | -1.5% | -11.8% | |
| Q4 2018 | +1.3% | +3.0% | -6.9% | |
| Q3 2018 | +0.2% | +3.4% | +3.7% | |
| Q2 2018 | -3.4% | -5.9% | +2.6% | |
| Q1 2018 | +1.8% | +2.2% | -24.8% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro